In breaking news, the Therapeutic Goods Administration has approved the Moderna Covid-19 vaccine to be trialled for use in young children aged 6 to 11 years of age.
Moderna Australia has submitted data about its use in younger children aged 6 to 11 which the TGA is assessing.
In a public statement the TGA said, "In making its decision to grant Moderna a provisional determination, the TGA considered evidence of a plan to submit comprehensive clinical data in relation to use in children. The TGA also considered infections in children and the impacts of COVID-19 in relation to children's participation in school and sporting activities. Moderna Australia has now submitted data for provisional approval and the TGA is assessing the use of SPIKEVAX in children 6 to 11 years old."